
Syneos Health SYNH
Quarterly report 2023-Q1
added 05-10-2023
Syneos Health Operating Cash Flow 2011-2026 | SYNH
Annual Operating Cash Flow Syneos Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 450 M | 425 M | 318 M | 303 M | 198 M | 109 M | 205 M | 131 M | 37.3 M | 43 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 450 M | 37.3 M | 222 M |
Quarterly Operating Cash Flow Syneos Health
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.4 M | - | - | - | 70.9 M | - | - | - | 127 M | - | 311 M | 155 M | -38.6 M | - | 158 M | 83.5 M | -13.3 M | - | 191 M | 65.2 M | -47 M | - | 110 M | 98.4 M | 75.7 M | - | 95.1 M | 44.4 M | -646 K | - | 141 M | 95.3 M | 43.6 M | - | 117 M | 80.4 M | 31.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 311 M | -47 M | 84.4 M |
Operating Cash Flow of other stocks in the Diagnostics research industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-21.7 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
65.4 M | - | -17.87 % | $ 25.9 M | ||
|
Bioventus
BVS
|
74.7 M | $ 8.93 | 0.68 % | $ 595 M | ||
|
Brainsway Ltd.
BWAY
|
884 K | $ 13.67 | 0.11 % | $ 99.4 M | ||
|
Castle Biosciences
CSTL
|
64.9 M | $ 25.81 | -0.08 % | $ 717 M | ||
|
Aspira Women's Health
AWH
|
-32.2 M | - | -6.19 % | $ 10.5 M | ||
|
DexCom
DXCM
|
1.44 B | $ 67.83 | 2.24 % | $ 26.5 B | ||
|
Guardant Health
GH
|
-185 M | $ 88.44 | 1.45 % | $ 11.1 B | ||
|
Charles River Laboratories International
CRL
|
738 M | $ 153.93 | 1.29 % | $ 7.63 B | ||
|
CareDx, Inc
CDNA
|
42 M | $ 17.54 | 1.27 % | $ 935 M | ||
|
Accelerate Diagnostics
AXDX
|
-48.7 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
491 M | $ 103.98 | 0.12 % | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
614 M | - | - | $ 399 M | ||
|
IQVIA Holdings
IQV
|
2.65 B | $ 168.58 | 2.24 % | $ 29 B | ||
|
Genetic Technologies Limited
GENE
|
-5.66 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-524 M | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
21.1 M | $ 15.54 | 3.95 % | $ 470 M | ||
|
Biodesix
BDSX
|
-48.6 M | $ 16.96 | -1.91 % | $ 2.2 B | ||
|
ICON Public Limited Company
ICLR
|
1.29 B | $ 99.21 | 1.63 % | $ 8.18 B | ||
|
Anixa Biosciences
ANIX
|
-7.17 M | $ 2.89 | 1.76 % | $ 93.8 K | ||
|
Danaher Corporation
DHR
|
6.42 B | $ 195.14 | 1.96 % | $ 139 B | ||
|
Biocept
BIOC
|
-13.3 M | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
-21.8 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-18.4 M | - | -20.0 % | $ 1.06 M | ||
|
Pacific Biosciences of California
PACB
|
-111 M | $ 1.42 | 4.41 % | $ 426 M | ||
|
Illumina
ILMN
|
837 M | $ 122.1 | 2.36 % | $ 19.4 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.89 B | $ 198.46 | -0.24 % | $ 22 B | ||
|
QIAGEN N.V.
QGEN
|
674 M | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
1.48 B | $ 113.8 | 1.76 % | $ 34.6 B | ||
|
BioNano Genomics
BNGO
|
-68.9 M | $ 1.13 | 1.67 % | $ 1.44 M | ||
|
DarioHealth Corp.
DRIO
|
-30.4 M | $ 9.04 | 7.36 % | $ 256 M | ||
|
NeoGenomics
NEO
|
5.23 M | $ 8.31 | 0.85 % | $ 1.06 B | ||
|
Neogen Corporation
NEOG
|
58.2 M | $ 9.22 | 1.21 % | $ 2 B | ||
|
Lantheus Holdings
LNTH
|
390 M | $ 80.11 | 2.05 % | $ 5.41 B | ||
|
Chembio Diagnostics
CEMI
|
-12.7 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-8 M | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
-22.1 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
713 M | $ 457.31 | 0.81 % | $ 13.2 B | ||
|
Motus GI Holdings
MOTS
|
-11.2 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
956 M | $ 1 218.7 | 1.67 % | $ 25.1 B | ||
|
Celcuity
CELC
|
-83.5 M | $ 115.13 | 0.2 % | $ 4.54 B | ||
|
DermTech
DMTK
|
-77 M | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
26.4 M | $ 17.58 | 1.03 % | $ 393 M | ||
|
Invitae Corporation
NVTA
|
-493 M | - | - | $ 21.2 M | ||
|
Twist Bioscience Corporation
TWST
|
-47.6 M | $ 47.21 | 4.89 % | $ 2.82 B | ||
|
Enzo Biochem
ENZ
|
-26.3 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
-432 M | $ 199.94 | 1.14 % | $ 19.7 B |